{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:28:57Z","timestamp":1788557337421,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40123-024-00935-w","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T13:02:01Z","timestamp":1714050121000},"page":"1723-1742","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Understanding Perspectives on Presbyopia and Use of Pilocarpine HCl 1.25% Twice Daily from Participants of the Phase 3 VIRGO Study"],"prefix":"10.1007","volume":"13","author":[{"given":"Brian M.","family":"Shafer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina R.","family":"McGee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristos","family":"Ifantides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake K.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Kannarr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Whyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuoyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Yanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Schachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"935_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ajo.2020.12.021","volume":"225","author":"GO Waring IV","year":"2021","unstructured":"Waring GO IV, Chang DH, Rocha KM, Gouvea L, Penatti R. Correlation of intraoperative optical coherence tomography of crystalline lens diameter, thickness, and volume with biometry and age. Am J Ophthalmol. 2021;225:147\u201356.","journal-title":"Am J Ophthalmol"},{"key":"935_CR2","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.3928\/1081597X-20210408-06","volume":"37","author":"RN Mercer","year":"2021","unstructured":"Mercer RN, Milliken CM, Waring GO IV, Rocha K. Future trends in presbyopia correction. J Refract Surg. 2021;37:S28\u201334.","journal-title":"J Refract Surg"},{"key":"935_CR3","unstructured":"American Optometric Association. Optometric clinical practice guideline\u2014care of the patient with presbyopia. St. Louis: American Optometric Association; 2011."},{"key":"935_CR4","unstructured":"GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Trends in prevalence of blindness and distance and near vision impairment over 30\u00a0years: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9:e130\u201343."},{"key":"935_CR5","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.3390\/jcm11051385","volume":"11","author":"A Grzybowski","year":"2022","unstructured":"Grzybowski A, Ruamviboonsuk V. Pharmacological treatment in presbyopia. J Clin Med. 2022;11:1385.","journal-title":"J Clin Med"},{"key":"935_CR6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/OPX.0000000000001913","volume":"99","author":"J Stokes","year":"2022","unstructured":"Stokes J, Shirneshan E, Graham CA, Paulich M, Johnson N. Exploring the experience of living with and managing presbyopia. Optom Vis Sci. 2022;99:635\u201344.","journal-title":"Optom Vis Sci"},{"key":"935_CR7","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.2147\/OPTH.S269597","volume":"14","author":"J Berdahl","year":"2020","unstructured":"Berdahl J, Bala C, Dhariwal M, Lemp-Hull J, Thakker D, Jawla S. Patient and economic burden of presbyopia: a systematic literature review. Clin Ophthalmol. 2020;14:3439\u201350.","journal-title":"Clin Ophthalmol"},{"key":"935_CR8","doi-asserted-by":"crossref","unstructured":"Wolffsohn JS, Davies LN, Sheppard AL. New insights in presbyopia: impact of correction strategies. BMJ Open Ophthalmol. 2023;8(1):e001122","DOI":"10.1136\/bmjophth-2022-001122"},{"key":"935_CR9","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.2147\/OPTH.S259011","volume":"15","author":"JA Katz","year":"2021","unstructured":"Katz JA, Karpecki PM, Dorca A, et al. Presbyopia\u2014a review of current treatment options and emerging therapies. Clin Ophthalmol. 2021;15:2167\u201378.","journal-title":"Clin Ophthalmol"},{"key":"935_CR10","unstructured":"Allergan, an AbbVie company. Highlights of prescribing information\u2014VUITYTM (pilocarpine hydrochloride ophthalmic solution) 1.25%, for topical ophthalmic use. 2023. https:\/\/www.rxabbvie.com\/pdf\/vuity_pi.pdf. Accessed 25 Jan 2024."},{"key":"935_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1001\/jamaophthalmol.2022.0059","volume":"140","author":"GO Waring IV","year":"2022","unstructured":"Waring GO IV, Price FW Jr, Wirta D, et al. Safety and efficacy of AGN-190584 in individuals with presbyopia: the GEMINI 1 phase 3 randomized clinical trial. JAMA Ophthalmol. 2022;140:363\u201371.","journal-title":"JAMA Ophthalmol"},{"key":"935_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ajo.2023.05.008","volume":"253","author":"S Kannarr","year":"2023","unstructured":"Kannarr S, El-Harazi SM, Moshirfar M, et al. Safety and efficacy of twice-daily pilocarpine HCl In presbyopia: the VIRGO phase 3, randomized, double-masked, controlled study. Am J Ophthalmol. 2023;253:189\u2013200.","journal-title":"Am J Ophthalmol"},{"key":"935_CR13","unstructured":"Wadhwa RR, Cascella M. Steady state concentration. [Updated 6 Mar 2023]. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK553132\/."},{"key":"935_CR14","unstructured":"Barnett M, McGee S, Pack W, Yuan J, Shirneshan E, Campbell J. No impact of headache or visual impairment adverse events following AGN-190584 observed on patient-reported outcomes. Denver: Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting, 1\u20134 May 2022."},{"key":"935_CR15","volume-title":"Interpreting clinically meaningful near vision improvement in presbyopia with AGN-190584 in the GEMINI 1 phase 3 trial","author":"DG Evans","year":"2021","unstructured":"Evans DG, Coon C, Nichols KK, Shirneshan E, Campbell J. Interpreting clinically meaningful near vision improvement in presbyopia with AGN-190584 in the GEMINI 1 phase 3 trial. Boston: American Academy of Optometry (AAOpt) Academy 2021 Annual Meeting, 3\u20136 November 2021."},{"key":"935_CR16","unstructured":"Wirta D, Christie W, Tauber J, Shirneshan E, Lee S, Campbell J. Assessing presbyopia impacts and coping behaviors with de novo PRO instruments in a phase 3 study of AGN-190584 (Pilocarpine 1.25%). Las Vegas: 2021 American Society of Cataract and Refractive Surgery Annual Meeting, 23\u201327 July 2021."},{"key":"935_CR17","unstructured":"McCabe CM, Wirta D, Price FWJ, Lee S, Shirneshan E, Campbell JT. Patient-reported outcomes in pooled phase 3 studies of AGN-190584 (Pilocarpine 1.25%) for presbyopia. New Orleans: American Academy of Ophthalmology 2021 Annual Meeting, 12\u201313 November 2021."},{"key":"935_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4135\/9781446221792.n3","volume-title":"Rethinking methods in psychology","author":"K Charmaz","year":"1995","unstructured":"Charmaz K. Grounded theory. In: Smith J, Harr\u00e9 R, Van Langenhove L, editors. Rethinking methods in psychology. London: Sage Publications; 1995. p. 27\u201349."},{"key":"935_CR19","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s11136-010-9677-6","volume":"19","author":"KE Lasch","year":"2010","unstructured":"Lasch KE, Marquis P, Vigneux M, et al. PRO development: rigorous qualitative research as the crucial foundation. Qual Life Res. 2010;19:1087\u201396.","journal-title":"Qual Life Res"},{"key":"935_CR20","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/0049124113500475","volume":"42","author":"JL Campbell","year":"2013","unstructured":"Campbell JL, Quincy C, Osserman J, Pedersen OK. Coding in-depth semistructured interviews: problems of unitization and intercoder reliability and agreement. Sociol Methods Res. 2013;42:294\u2013320.","journal-title":"Sociol Methods Res"},{"key":"935_CR21","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1177\/1049732316665344","volume":"27","author":"MM Hennink","year":"2017","unstructured":"Hennink MM, Kaiser BN, Marconi VC. Code saturation versus meaning saturation: how many interviews are enough? Qual Health Res. 2017;27:591\u2013608.","journal-title":"Qual Health Res"},{"key":"935_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L. How many interviews are enough?: an experiment with data saturation and variability. Field Methods. 2006;18:59\u201382.","journal-title":"Field Methods"},{"key":"935_CR23","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/aos.12308","volume":"92","author":"AD Goertz","year":"2014","unstructured":"Goertz AD, Stewart WC, Burns WR, Stewart JA, Nelson LA. Review of the impact of presbyopia on quality of life in the developing and developed world. Acta Ophthalmol. 2014;92:497\u2013500.","journal-title":"Acta Ophthalmol"},{"key":"935_CR24","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ajo.2007.12.011","volume":"145","author":"BP Luo","year":"2008","unstructured":"Luo BP, Brown GC, Luo SC, Brown MM. The quality of life associated with presbyopia. Am J Ophthalmol. 2008;145:618\u201322.","journal-title":"Am J Ophthalmol"},{"key":"935_CR25","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1001\/archopht.121.11.1577","volume":"121","author":"PJ McDonnell","year":"2003","unstructured":"McDonnell PJ, Lee P, Spritzer K, Lindblad AS, Hays RD. Associations of presbyopia with vision-targeted health-related quality of life. Arch Ophthalmol. 2003;121:1577\u201381.","journal-title":"Arch Ophthalmol"},{"key":"935_CR26","doi-asserted-by":"publisher","unstructured":"Waring GO 4th, Brujic M, McGee S, et al. Impact of presbyopia treatment pilocarpine hydrochloride 1.25% on night-driving performance. Clin Exp Optom. 2023;1\u20138. https:\/\/doi.org\/10.1080\/08164622.2023.2279189.","DOI":"10.1080\/08164622.2023.2279189"},{"key":"935_CR27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12886-022-02432-9","volume":"22","author":"M Brujic","year":"2022","unstructured":"Brujic M, Kruger P, Todd J, et al. Living with presbyopia: experiences from a virtual roundtable dialogue among impacted individuals and healthcare professionals. BMC Ophthalmol. 2022;22:204.","journal-title":"BMC Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-024-00935-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-024-00935-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-024-00935-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T12:32:36Z","timestamp":1716294756000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-024-00935-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["935"],"URL":"https:\/\/doi.org\/10.1007\/s40123-024-00935-w","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"assertion":[{"value":"15 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Brian M Shafer has received consulting fees, honoraria, speaker fees, and\/or travel reimbursement from Alcon, Allergan (an AbbVie company), CorneaGen, Harrow Pharmaceuticals, Tarsus, and Visus Therapeutics. Selina R McGee has received consulting fees, honoraria, speaker fees, and\/or travel reimbursement from Allergan (an AbbVie company), Bausch\u2009+\u2009Lomb, Bruder, Cynosure, Dompe, EyeVance, Horizon, Kala Pharmaceuticals, Lumenis, Novartis, Ocuphire, Optovue, Osmotica, Oyster Point, Sun Pharmaceutical, Tarsus, Thea, and Versant. Cristos Ifantides has received consulting fees, honoraria, speaker fees, and\/or travel reimbursement from Ace Vision Group, Acufocus Inc, Alcon, Allergan (an AbbVie company), Bausch\u2009+\u2009Lomb, BVI, Centricity Vision, Hu-Med Technologies, Johnson & Johnson, New World Medical, Spect Inc, Tarsus, Trefoil, Vision 2020 USA, Visus Therapeutics, and Zeiss. Cristos Ifantides\u2019 spouse is an employee of AbbVie and may hold AbbVie stock. Blake K Williamson has received consulting fees from Allergan (an AbbVie company), Bausch\u2009+\u2009Lomb, BVI, Glaukos, Johnson & Johnson, New World Medical, Sight Sciences, Staar, and Zeiss. Shane Kannarr has received consulting fees, honoraria, speaker fees, and\/or travel reimbursements from Alcon Vision, Allergan (an AbbVie company), Bausch\u2009+\u2009Lomb, Essilor, Johnson & Johnson, Kala Pharmaceuticals, Novartis, Osmotica, Sight Sciences, Sun Pharmaceutical, Tarsus, and Vision Source. Julie Whyte is a full-time employee of Endpoint Outcomes, a Lumanity company. Zuoyi Zhang, Travis Yanke, and Scott Schachter are or were full-time employees of AbbVie and may hold AbbVie stock.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The protocol was prospectively approved (on 17 December 2021) by the Western Copernicus Group Institutional Review Board (tracking number: 20216789) before any of the participants were contacted. The study was conducted in accordance with ethical principles of the Declaration of Helsinki and followed the guidelines of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and applicable regulatory requirements. Individuals who agreed to participate provided written informed consent before initiating the companion study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}